These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19723306)

  • 21. The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia.
    Du Q; Wang L; Zhu H; Zhang S; Xu L; Zheng W; Liu X
    Med Oncol; 2010 Sep; 27(3):673-9. PubMed ID: 19653139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
    Zhang WW; Cortes JE; Yao H; Zhang L; Reddy NG; Jabbour E; Kantarjian HM; Jones D
    J Clin Oncol; 2009 Aug; 27(22):3642-9. PubMed ID: 19506164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.
    Jiang X; Forrest D; Nicolini F; Turhan A; Guilhot J; Yip C; Holyoake T; Jorgensen H; Lambie K; Saw KM; Pang E; Vukovic R; Lehn P; Ringrose A; Yu M; Brinkman RR; Smith C; Eaves A; Eaves C
    Blood; 2010 Sep; 116(12):2112-21. PubMed ID: 20574046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
    Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
    Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
    Aceves-Luquero CI; Agarwal A; Callejas-Valera JL; Arias-González L; Esparís-Ogando A; del Peso Ovalle L; Bellón-Echeverria I; de la Cruz-Morcillo MA; Galán Moya EM; Moreno Gimeno I; Gómez JC; Deininger MW; Pandiella A; Sánchez Prieto R
    PLoS One; 2009 Jul; 4(7):e6124. PubMed ID: 19568437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
    Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
    Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1.
    Lu YH; Huang ZY
    Mol Med; 2021 Nov; 27(1):148. PubMed ID: 34781898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
    Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
    Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
    Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele.
    Virgili A; Koptyra M; Dasgupta Y; Glodkowska-Mrowka E; Stoklosa T; Nacheva EP; Skorski T
    Cancer Res; 2011 Aug; 71(16):5381-6. PubMed ID: 21693657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T; Eide CA; Deininger MW
    Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
    Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
    Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia.
    Mitchell B; Deininger M
    Leuk Lymphoma; 2011 Feb; 52 Suppl 1():4-11. PubMed ID: 21299455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
    Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
    J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
    Aloisi A; Di Gregorio S; Stagno F; Guglielmo P; Mannino F; Sormani MP; Bruzzi P; Gambacorti-Passerini C; Saglio G; Venuta S; Giustolisi R; Messina A; Vigneri P
    Blood; 2006 Feb; 107(4):1591-8. PubMed ID: 16249386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
    Barbouti A; Ahlgren T; Johansson B; Höglund M; Lassen C; Turesson I; Mitelman F; Fioretos T
    Br J Haematol; 2003 Jul; 122(1):85-93. PubMed ID: 12823349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.